First Manhattan’s Intellia Therapeutics NTLA Stock Holding History

First Manhattan’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-105	Closed	-$5K	–	1759
2022 Q3	$5K	Hold	105	–	–	﹤0.01%	1313
2022 Q2	$5K	Hold	105	–	–	﹤0.01%	1339
2022 Q1	$7K	Sell	105 -66	-39%	-$5.59K	﹤0.01%	1336
2021 Q4	$20K	Hold	171	–	–	﹤0.01%	1169
2021 Q3	$22K	Buy	171 +66	+63%	+$9.99K	﹤0.01%	1152
2021 Q2	$17K	Hold	105	–	–	﹤0.01%	1185
2021 Q1	$8K	Buy	+105	New	+$7.05K	﹤0.01%	1273

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

First Manhattan's NTLA Position: Q4 2022 in Review

First Manhattan sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 105 shares — an estimated $5K sold.

First Manhattan first reported a position in NTLA in Q1 2021 and held it in 7 quarters. The position peaked at $22K in Q3 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

First Manhattan reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 105 Intellia Therapeutics shares in Q4 2022, an estimated $5K.
First Manhattan first reported a position in Intellia Therapeutics in Q1 2021 and held it in 7 quarters.
First Manhattan's Intellia Therapeutics position peaked at $22K in Q3 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.